An injectable shape-adaptive hydrogel system for subconjunctival injuries: and permanently releases rapamycin to prevent fibrosis promoting autophagy.

Subconjunctival fibrosis (SCF) is a common and refractory eye disease that is a serious threat to vision. The severe side effects of existing drugs and low drug bioavailability due to the ocular barrier are major challenges in SCF treatment. Hence, there is an urgent need to explore safer and more effective strategies for administering anti-SCF drugs.